Genentech is letting go of 87 employees at its South San Francisco headquarters, the second round of layoffs at the Roche subsidiary this year.
All entries for: Home
July 25, 2025
Genentech
Layoffs
San Francisco, CA
10,001-50,000 employees
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
July 24, 2025
Tessera Therapeutics
Layoffs
Somerville, MA
201-500 employees
Tessera Therapeutics will reduce its workforce by 17%, according to reporting from Fierce Biotech, which confirmed the layoffs with a company spokesperson. The move will help support Tessera’s transition into clinical work later this year. It is unclear when the layoffs will take effect or how many exactly will be affected.
Disease Area: Chronic Disease, Multiple, Rare Diseases, Respiratory Diseases
Drug Type: Biologic
July 24, 2025
Replimune
Negative Outlook
Woburn, MA
201-500 employees
We cannot be sure whether additional legislation related to the IRA will be issued or enacted, or what impact, if any, such changes will have on the profitability of any of our drug candidates, if approved for commercial use, in the future. There also may be future changes unrelated to the IRA that result in reductions in potential coverage and reimbursement levels for our product candidates, if approved and commercialized, and we cannot predict the scope of any future changes or the impact that those changes would have on our operations.
Disease Area: Oncology
Drug Type: Biologic, Small Molecule
July 24, 2025
Hyperion Defi Inc
Negative Outlook
Laguna Hills, CA
1-50 employees
We expect that federal, state and local governments in the United States, as well as foreign governments, will continue to consider legislation directed at lowering the total cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize any product that is ultimately approved, if approved. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad.
Disease Area: Chronic Disease, Multiple, Neurological Diseases
Drug Type: Small Molecule
July 21, 2025
GSK - Cambridge
Layoffs
Cambridge, MA
50,001+ employees
GSK is letting go of 150 employees in Cambridge, Massachusetts, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. Endpoints News reported that the London-based company plans to move manufacturing of its pneumococcal vaccine asset that uses its multiple antigen presenting system (MAPS) technology from Cambridge to Marietta, Pennsylvania.
Disease Area: Antiviral, Immune Diseases, Multiple, Oncology, Respiratory Diseases
Drug Type: Biologic, Small Molecule
July 21, 2025
BioNTech
Layoffs
Gaithersburg, MD
5,001-10,000 employees
Germany-based BioNTech is again cutting staff in Gaithersburg, Maryland, this time affecting 32 employees, according to a July 18 Worker Adjustment and Retraining Notification (WARN) Act notice. The layoffs at the biotech’s office and lab space at 25 West Watkins Mill Road are effective Sept. 16.
Disease Area: Immune Diseases
Drug Type: Biologic, Small Molecule
July 18, 2025
Sarepta Therapeutics
Layoffs
Cambridge, MA
1,001-5,000 employees
After a difficult season that has seen two deaths linked to Sarepta Therapeutics’ Duchenne muscular dystrophy treatment Elevidys, the Cambridge, Massachusetts–based biotech is letting go of more than a third of its workforce and adding a black box warning for acute liver injury and acute liver failure to the gene therapy. In a July 16 announcement, Sarepta revealed it will part with around 500 employees after a strategic review and focus its pipeline on “high-impact programs, prioritizing potentially best-in-class siRNA platform assets.” These include programs for facioscapulohumeral muscular dystrophy, idiopathic pulmonary fibrosis and Huntington’s disease.
Disease Area: Chronic Disease, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic
July 17, 2025
GSK
Layoffs
London, UK
50,001+ employees
London-based GSK is cutting its global research and development team by an unspecified number of people, Fierce Biotech reported July 15. A spokesperson told Fierce a “very limited number of positions will be impacted” across the company’s R&D workforce of more than 12,000 people.
Disease Area: Immune Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
July 14, 2025
Karyopharm Therapeutics
Layoffs
Newton, MA
201-500 employees
As it continues exploring options to extend its cash runway, which could include a merger or sale, Karyopharm Therapeutics is cutting about 20% of its workforce, according to a July 11 SEC filing. The Newton, Massachusetts–based commercial-stage pharma did not specify which locations the layoffs affect.
Disease Area: Hematology, Multiple, Oncology
Drug Type: Small Molecule
July 14, 2025
Azurity Pharmaceuticals
Layoffs
Wilmington, MA
501-1,000 employees
Azurity Pharmaceuticals is cutting 75 employees effective Sept. 12 through Dec. 31 in Wilmington, Massachusetts, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. The specialty pharma company’s website lists that location as a manufacturing and operating facility.
Disease Area: Cardiology, Gastrointestinal, Multiple, Neurological Diseases
Drug Type: Small Molecule